Koizumi Y, Obata H, Hara A, Nishimura T, Sakamoto K, Fujiyama Y. A case of scirrhous gastric cancer with peritonitis carcinomatosa controlled by TS-1® + paclitaxel for 36 mo after diagnosis. World J Gastroenterol 2007; 13(3): 470-473 [PMID: 17230622 DOI: 10.3748/wjg.v13.i3.470]
Corresponding Author of This Article
Dr. Yusuke Koizumi, Department of Gastroenterology and Hematology, Shiga University of Medical Science, Seta-Tsukinowa-cho, Otsu, Shiga 520-2192,Japan. yjkoizumi-1975@s9.dion.ne.jp
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Yusuke Koizumi, Takashi Nishimura, Yoshihide Fujiyama, Department of Gastroenterology and Hematology, Shiga University of Medical Science, Otsu, Japan
Hirozumi Obata, Kenichiro Sakamoto, Department of Medicine, Saiseikai Suita Hospital, Suita, Japan
Akinori Hara, Department of Surgery, Saiseikai Suita Hopspital, Suita, Japan
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Yusuke Koizumi, Department of Gastroenterology and Hematology, Shiga University of Medical Science, Seta-Tsukinowa-cho, Otsu, Shiga 520-2192,Japan. yjkoizumi-1975@s9.dion.ne.jp
Telephone: +81-77-5482217 Fax: +81-77-5482219
Received: November 11, 2006 Revised: December 1, 2006 Accepted: December 12, 2006 Published online: January 21, 2007
Abstract
A 34-year-old female complaining of abdominal fullness was diagnosed as scirrhous gastric cancer (type 4’) with peritonitis carcinomatosa in July 2002. A combined chemotherapy regimen was selected to control massive ascites; TS-1® 80 mg/m2 was given orally on d 1-14, 22-35, and paclitaxel 50 mg/m2 was administered intravenously on d 1, 8, 22 and 29. After 2 courses of this regimen, the primary tumor was markedly reduced, and ascites completely vanished. Alopecia (grade 1, since d 30), leukocytopenia (grade 2, on d 34) and anemia (grade 2, on d 34) were the only adverse events throughout the following courses. The chemotherapy was effective for 28 mo, and then it was discontinued upon the patient’s own request, and she survived for 36 mo after diagnosis.
